ArticlePostepy w kardiologii interwencyjnej = Advances in interventional cardiology2025
Predictive value of circulating cardiomyocyte-specific cell-free DNA levels for heart failure risk after acute ST-segment elevation myocardial infarction.
Article in Postepy w kardiologii interwencyjnej = Advances in interventional cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The onset of heart failure (HF) often signifies disease progression and unfavorable prognoses in cases of acute ST-segment elevation myocardial infarction (STEMI). Aim: To explore the potential value of circulating cardiomyocyte-specific cell-free DNA (CS cfDNA) levels as an indicator for predicting risk of HF after acute STEMI. Material and methods: Overall, 146 STEMI patients were included and classified into two groups according to CS cfDNA levels at admission: Group N1: ≤ 164 copies/ml, Group N2: > 164 copies/ml. A follow-up period of approximately 355 days was completed. Results: The prevalence of HF in Group N2 was significantly higher than that in Group N1 (77.4% vs. 18.3%,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.